Introduction:
Drug discovery company Evotec SE has formed a partnership with Inserm, Lille University Hospital, and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases. The partnership aims to identify novel therapeutic targets that complement existing drugs for obesity and diabetes.
- The partnership aims to identify new therapeutic targets for obesity and metabolic diseases.
- The collaboration will utilize a biobank of obesity-related clinical data and human biological samples.
- Evotec will perform omics studies to generate large datasets of molecular data.
- The data will be analyzed to identify and validate key mechanisms of obesity and other metabolic diseases.
- The partnership aims to develop more effective and safer treatment options for obesity and metabolic diseases.
Conclusion:
The partnership between Evotec, Inserm, Lille University Hospital, and Inserm Transfert aims to advance the understanding of obesity and metabolic diseases and develop improved treatment options. The collaboration will utilize a biobank of clinical data and human biological samples to identify novel therapeutic targets. This research has the potential to benefit the growing number of individuals affected by obesity and metabolic diseases worldwide.
